Results 1 to 10 of about 61,964 (279)

Scleroderma‐Specific Autoantibodies and Disease Trajectories in Early Systemic Sclerosis: Insights From a Single‐Center Prospective Registry [PDF]

ACR Open Rheumatology
Objective Early diffuse cutaneous systemic sclerosis (dcSSc) is associated with substantial disease‐specific mortality.  Scleroderma‐specific autoantibodies (SSc‐Ab) may influence disease course, but their prognostic value in very early dcSSc remains ...
Marzieh Jamali, Amisha Kaur, Suiyuan Huang, Carleigh Zahn, Erica Mulcaire‐Jones, John Varga, Dinesh Khanna   +6 more
doaj   +3 more sources

Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype? [PDF]

PLoS ONE, 2008
Scleroderma is an autoimmune disease with a characteristic vascular pathology. The vasculopathy associated with scleroderma is one of the major contributors to the clinical manifestations of the disease.We used immunohistochemical and mRNA in situ ...
David Fiorentino, Robert Lafyatis, Howard M Shulman   +2 more
exaly   +2 more sources

Infections of scleroderma digital ulcers: a single center cohort retrospective study

Dermatology Reports, 2021
BACKGROUNDS: Systemic Sclerosis (SSc) is a complex autoimmune and up to fifty percent of patients develop digital ulcers. AIMS: Understand how much infections influence scleroderma digital ulcers’ healing.
Dilia Giuggioli, Luca Magnani, Amelia Spinella, Gianluigi Bajocchi, Adalgisa Palermo, Federica Lumetti, Emanuele Cocchiara, Carlo Salvarani   +7 more
doaj   +1 more source

The Role of Bronchoalveolar Lavage in Systemic Sclerosis Interstitial Lung Disease: A Systematic Literature Review

Pharmaceuticals, 2022
The role of Bronchoalveolar Lavage (BAL) in the evaluation of systemic sclerosis (SSc) interstitial lung disease (ILD) is still controversial. The aim of this systematic literature review was to investigate the use of BAL in SSc-ILD, and to focus on the ...
Martina Orlandi, Laura Antonia Meliante, Arianna Damiani, Lorenzo Tofani, Cosimo Bruni, Serena Guiducci, Marco Matucci-Cerinic, Silvia Bellando-Randone, Sara Tomassetti   +8 more
doaj   +1 more source

Correction to: Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis

Arthritis Research & Therapy, 2021
An amendment to this paper has been published and can be accessed via the original article.
David A. Fox, Steven K. Lundy, Michael L. Whitfield, Veronica Berrocal, Phillip Campbell, Stephanie Rasmussen, Ray Ohara, Alexander Stinson, Mikel Gurrea-Rubio, Evan Wiewiora, Catherine Spino, Erica Bush, Daniel Furst, Shiv Pillai, Dinesh Khanna   +14 more
doaj   +1 more source

Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis

Arthritis Research & Therapy, 2021
Background Abnormalities in lymphocyte surface markers and functions have been described in systemic sclerosis (SSc), but conflicting results abound, and these studies often examined patients with heterogeneous disease duration, severity, clinical ...
David A. Fox, Steven K. Lundy, Michael L. Whitfield, Veronica Berrocal, Phillip Campbell, Stephanie Rasmussen, Ray Ohara, Alexander Stinson, Mikel Gurrea-Rubio, Evan Wiewiora, Catherine Spino, Erica Bush, Daniel Furst, Shiv Pillai, Dinesh Khanna   +14 more
doaj   +1 more source

Fibroblast A20 governs fibrosis susceptibility and its repression by DREAM promotes fibrosis in multiple organs

Nature Communications, 2022
A20 gene variants are linked with systemic sclerosis (SS), but the mechanisms are unclear. Here, the authors show that A20 expression is reduced in SS skin and lungs, that its ablation in mice induces SS, and that show that fibrosis can be ameliorated by
Wenxia Wang, Swarna Bale, Jun Wei, Bharath Yalavarthi, Dibyendu Bhattacharyya, Jing Jing Yan, Hiam Abdala-Valencia, Dan Xu, Hanshi Sun, Roberta G. Marangoni, Erica Herzog, Sergejs Berdnikovs, Stephen D. Miller, Amr H. Sawalha, Pei-Suen Tsou, Kentaro Awaji, Takashi Yamashita, Shinichi Sato, Yoshihide Asano, Chinnaswamy Tiruppathi, Anjana Yeldandi, Bettina C. Schock, Swati Bhattacharyya, John Varga   +23 more
doaj   +1 more source

Collaboration between patient organisations and a clinical research sponsor in a rare disease condition: learnings from a community advisory board and best practice for future collaborations

BMJ Open, 2020
Introduction Transparent collaborations between patient organisations (POs) and clinical research sponsors (CRS) can identify and address the unmet needs of patients and caregivers.
Ilaria Galetti, Maureen Sauve, Catarina Leite, Joep Welling, Martina Gahlemann, Annelise Roennow, Robert J Riggs, Ann Tyrrell Kennedy, Edith Brown, Alex Gonzalez, Alexandra Paula Portales Guiraud, François Houÿez, Rob Camp, Annie Gilbert, Lizette Moros, Jose Luis Luna Flores, Friedrich Schmidt, Wiebke Sauter, Henrik Finnern   +18 more
doaj   +1 more source

Global gene expression analysis of systemic sclerosis myofibroblasts demonstrates a marked increase in the expression of multiple NBPF genes

Scientific Reports, 2021
Myofibroblasts are the key effector cells responsible for the exaggerated tissue fibrosis in Systemic Sclerosis (SSc). Despite their importance to SSc pathogenesis, the specific transcriptome of SSc myofibroblasts has not been described.
Giuseppina Abignano, Heidi Hermes, Sonsoles Piera-Velazquez, Sankar Addya, Francesco Del Galdo, Sergio A. Jimenez   +5 more
doaj   +1 more source

Pharmacological Inhibition of Toll-Like Receptor-4 Signaling by TAK242 Prevents and Induces Regression of Experimental Organ Fibrosis

Frontiers in Immunology, 2018
Systemic sclerosis (SSc) is a poorly understood heterogeneous condition with progressive multi-organ fibrosis. Recent genetic and genomic evidence suggest a pathogenic role for dysregulated innate immunity and toll-like receptor (TLR) activity in SSc ...
Swati Bhattacharyya, Wenxia Wang, Zenshiro Tamaki, Bo Shi, Anjana Yeldandi, Yasuhiro Tsukimi, Masashi Yamasaki, John Varga   +7 more
doaj   +1 more source